Suppr超能文献

骨髓增殖性疾病中血小板血小板源性生长因子含量的可逆性缺陷。

A reversible defect of platelet PDGF content in myeloproliferative disorders.

作者信息

Baglin T P, Price S M, Boughton B J

机构信息

Department of Haematology, Queen Elizabeth Medical Centre, Edgbaston, Birmingham.

出版信息

Br J Haematol. 1988 Aug;69(4):483-6. doi: 10.1111/j.1365-2141.1988.tb02403.x.

Abstract

Platelet PDGF (platelet derived growth factor), platelet associated IgG and plasma levels of circulating immune complexes were measured in patients with chronic myeloproliferative disorders (primary myelofibrosis, primary proliferative polycythaemia and essential thrombocythaemia). Platelet PDGF was low in 11/12 patients, immune complexes were elevated in 11/16, and PlAIgG was elevated in all 14 patients in whom it was measured. There was no significant correlation between platelet PDGF and plasma levels of immune complexes (r = -0.5, P greater than 0.1). Treatment with busulphan and prednisolone for 2-3 months restored normal levels of platelet PDGF and suppressed plasma immune complex levels. Plasmapheresis lowered levels of immune complexes but had no effect on platelet PDGF. These results indicate that the low platelet PDGF levels in chronic myeloproliferative disorders represent a reversible defect which is not directly related to the presence of immune complexes.

摘要

对慢性骨髓增殖性疾病(原发性骨髓纤维化、原发性增殖性红细胞增多症和原发性血小板增多症)患者测定了血小板源性生长因子(PDGF)、血小板相关免疫球蛋白G(PlAIgG)以及循环免疫复合物的血浆水平。12例患者中有11例血小板PDGF水平较低,16例中有11例免疫复合物水平升高,在测定的所有14例患者中PlAIgG均升高。血小板PDGF与免疫复合物的血浆水平之间无显著相关性(r = -0.5,P>0.1)。用白消安和泼尼松治疗2 - 3个月可使血小板PDGF水平恢复正常,并抑制血浆免疫复合物水平。血浆置换可降低免疫复合物水平,但对血小板PDGF无影响。这些结果表明,慢性骨髓增殖性疾病中血小板PDGF水平低代表一种可逆性缺陷,与免疫复合物的存在无直接关系。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验